Quarterly ResultMay 12, 2026, 04:18 PM
CalciMedica Reports Net Income $5.0M; Going Concern Doubt Raised
AI Summary
CalciMedica, Inc. reported a net income of $5.0 million for the three months ended March 31, 2026, a significant improvement from a net loss of $5.0 million in the prior year period. Despite this, the company maintains an accumulated deficit of $184.4 million and its management has raised substantial doubt about its ability to continue as a going concern, citing insufficient cash and cash equivalents to fund operations for the next year. The company plans to seek additional funding through various financing and collaboration agreements.
Key Highlights
- Net income was $5.0 million for the three months ended March 31, 2026, compared to a net loss of $5.0 million in 2025.
- Accumulated deficit was $184.4 million as of March 31, 2026.
- Cash and cash equivalents were $8.2 million as of March 31, 2026, down from $11.5 million at December 31, 2025.
- Total liabilities were $9.7 million as of March 31, 2026, down from $20.2 million at December 31, 2025.
- Total stockholders' deficit improved to $(1.1) million as of March 31, 2026, from $(6.6) million at December 31, 2025.
- Research and development expenses decreased to $3.5 million from $4.2 million year-over-year.
- General and administrative expenses decreased to $2.1 million from $2.3 million year-over-year.
- Management believes cash and cash equivalents may not be sufficient to fund operations for one year, raising substantial doubt about going concern.